GlobeNewswire

PCI Biotech to present at BIO-Europe 2019

Share

Oslo, Norway, November 12, 2019 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present at BIO-Europe 2019 being held November 11-13, 2019 at Hamburg Messe, Germany.

On Wednesday, November 13, 2019 at 09:15am (CET), Dr. Per Walday, CEO, will present an overview of PCI Biotech’s technology and the multiple business development and commercial opportunities available based on this proprietary platform. The presentation will be made available on PCI Biotech’s website (www.pcibiotech.com ) under “Other presentations”.

About PCI Biotech         
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

Contact information:   
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway. www.pcibiotech.com      
Ronny Skuggedal, CFO, rs@pcibiotech.com , Mobile: +47 9400 5757.

Forward-looking statements  
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Recording of the Third Quarter 2019 Investor Conference Webinar11.12.2019 18:22:00 CETPress release

On December 11 JSC Olainfarm organized its Investor Conference Online Webinar. During the webinar the Chairman of Management Board Jeroen Weites and Investor Relations Advisor Janis Dubrovskis analyzed the financial results of third quarter and 9 months 2019 and informed about other recent activities within the company. The recorded webinar is available online: https://bit.ly/2sg4rPa, and the presentation, demonstrated during the webinar, is available in the attachment. Methodology for alternative performance indicators is disclosed in Annual report for 2018 (page 20) and in Financial statements for 6 months period ended 30 June 2019 (page 17). Olainfarm thanks all participants, who joined the webinar, and encourages everybody to follow company’s announcements to get information on the next webinar! JSC Olainfarm is one of the largest companies in the Baltic States with more than 45 years of experience in production of pharmaceuticals and chemical and pharmaceutical products. The basic

Volta Finance Limited - Net Asset Value as at 30 November 201911.12.2019 18:15:00 CETPress release

Volta Finance Limited (VTA / VTAS) – November 2019 monthly report NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ***** Guernsey, 11 December 2019 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for November. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). PERFORMANCE and PORTFOLIO ACTIVITY In November, Volta’s NAV* total return performance was +0.4%. The YTD performance is 3.5%. This month, performance was mainly driven by a modest rebound in both CLO debt and CLO Equity prices. The monthly performances ** of the sub-asset classes were the following, in local currency: +1.0% for Bank Balance Sheet transactions, +0.9% for CLO Equity tranches; +0.8% for CLO Debt; +0.7% for Cash Corporate Credit deals; and +0.2% for ABS. Once again this month, CLO Equity positions outperformed CLO Debt (with the strongest performe

Millicom files standard form for notification of major holdings11.12.2019 18:11:00 CETPress release

Millicom files standard form for notification of major holdings Luxembourg, December 11, 2019 – Millicom International Cellular SA (“Millicom”) announced today the CSSF regulatory filing of the form: ANNEX A: Standard form for notification of major holdings (attachment) -END- For further information, please contact Press: Vivian Kobeh, Corporate Communications Director +1 786 628 5300 press@millicom.com Investors: Michel Morin, VP Investor Relations +1 786 628 5270 investors@millicom.com Sarah Inmon, Investor Relations Manager +1-786-628-5303 investors@millicom.com About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of cable and mobile services dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing high-speed broadband and innovation around The Digital Lifestyle services through its principal brand, TIGO. As of December 31st, 2018, Millicom operating subsidiaries and joint ventures employed

SBM Offshore signs FPSO Sepetiba contracts11.12.2019 18:09:00 CETPress release

December 11, 2019 SBM Offshore is pleased to announce it has signed contracts with Petróleo Brasileiro S.A. (Petrobras) for the 22.5 years lease and operation of FPSO Sepetiba (formerly known as Mero 2). These contracts follow the signing of the binding Letter of Intent (LOI) as announced on June 11, 2019. FPSO Sepetiba will be deployed at the Mero field in the Santos Basin offshore Brazil, 180 kilometers offshore Rio de Janeiro. SBM Offshore is progressing with the design and construction using its industry leading Fast4Ward® program as it incorporates the Company’s new build, multi-purpose hull combined with several standardized topsides modules. Delivery of the FPSO is expected in 2022. The Libra block, where the Mero field is located, is under Production Sharing Agreement to a Consortium comprised of Petrobras, as the Operator, with 40 percent, Shell with 20 percent, Total with 20 percent, CNODC with 10 percent and CNOOC Limited with 10 percent interest. The Consortium also has the

Floris Deckers to retire as Chairman of the Supervisory Board11.12.2019 18:00:00 CETPress release

December 11, 2019 At the Annual General Meeting (AGM) of April 8, 2020 Floris Deckers will retire as Chairman of the Supervisory Board after having completed the maximum 12 years of service. It is the intention of the Supervisory Board to appoint Roeland Baan as successor. Roeland Baan joined the Supervisory Board in 2018. At the AGM Tom Ehret will also retire after having completed the maximum 12 years of service. The Supervisory Board is concluding the process for succession. The Supervisory Board further announces its intention to propose to the AGM to reappoint Bruno Chabas as CEO. The full agenda of the AGM of 2020 will be published on February 26, 2020. Corporate Profile SBM Offshore N.V. is a listed holding company that is headquartered in Amsterdam. It holds direct and indirect interests in other companies that collectively with SBM Offshore N.V. form the SBM Offshore Group (“the Company”). SBM Offshore provides floating production solutions to the offshore energy industry, ove

Kiadis Pharma announces change to management board11.12.2019 17:45:00 CETPress release

Amsterdam, The Netherlands, December 11, 2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that Scott A. Holmes, the Company’s chief financial officer and member of the Company’s management board, is stepping down to pursue other opportunities. Mr. Holmes’ resignation will be effective December 31, 2019. “I want to thank Scott for his contributions to Kiadis; on behalf of the supervisory board and myself, we wish Scott well in his future endeavors,” Arthur Lahr, CEO of Kiadis commented. “Following our recent restructuring, Kiadis is an earlier stage company with a strong management team to advance our Company through our next phase of growth. As such, we do not plan to fill the CFO role as Scott’s responsibilities can be taken over by other management team members, specifically Amy Sullivan and Paul van Hagen.” Ms. Sullivan joined Kiadis in January 2019 as SVP, corporate affairs and